Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Atreca, Inc. BCEL
$1.07
+$0.13 (12.22%)
На 18:01, 12 мая 2023
+273.83%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
43072259.00000000
-
week52high
2.80
-
week52low
0.76
-
Revenue
0
-
P/E TTM
0
-
Beta
1.08161200
-
EPS
-2.39000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Stifel | Buy | Buy | 04 мар 2022 г. |
| Jefferies | Buy | 08 февр 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 12 авг 2020 г. |
| Wedbush | Outperform | 22 апр 2020 г. | |
| H.C. Wainwright | Buy | 22 апр 2020 г. | |
| Wedbush | Outperform | Outperform | 15 ноя 2022 г. |
| EF Hutton | Buy | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bishop Philippe C | A | 350000 | 350000 | 09 янв 2023 г. |
| Courtney Phillips | D | 29068 | 6432 | 02 сент 2022 г. |
| CROSS HERB | D | 34554 | 7646 | 02 сент 2022 г. |
| Orwin John A | D | 100492 | 20908 | 02 сент 2022 г. |
| Serafini Tito | D | 34554 | 7646 | 02 сент 2022 г. |
| Serafini Tito | D | 228875 | 15000 | 28 июн 2022 г. |
| Gould Stephen E | A | 200000 | 200000 | 15 июн 2022 г. |
| Serafini Tito | D | 0 | 50145 | 13 июн 2022 г. |
| Serafini Tito | D | 50145 | 50145 | 13 июн 2022 г. |
| Serafini Tito | D | 141395 | 141395 | 13 июн 2022 г. |
Новостная лента
Atreca, Inc. (BCEL) Q4 2022 Earnings Call Transcript
Seeking Alpha
29 мар 2023 г. в 20:36
Atreca, Inc. (NASDAQ:BCEL ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Alex Gray - Head of Investor Relations John Orwin - CEO Tito Serafini - Chief Strategy Officer and Founder Philippe Bishop - Chief Medical Officer Stephen Gould - Chief Scientific Officer Herb Cross - Chief Financial Officer Conference Call Participants Divya Rao - Cowen Roger Song - Jefferies John Newman - Canaccord Tony Butler - EF Hutton Stephen Willey - Stifel Kemp Dolliver - Brookline Capital Operator Thank you for standing by. Welcome to the Atreca's Fourth Quarter and Year End 2022 Earnings Call.
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
GlobeNewsWire
23 мар 2023 г. в 17:00
Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101 Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101
Why Is Atreca (BCEL) Stock Up Today?
InvestorPlace
14 февр 2023 г. в 09:47
Atreca (NASDAQ: BCEL ) stock is getting a boost on Tuesday as the company continues a recent rally connected to insider buying. On Monday, shares of BCEL stock jumped nearly 14% after a series of filings with the U.S. Securities and Exchange Commission (SEC).
Atreca Locks In A Catalyst In The Oncology Space
Seeking Alpha
01 февр 2023 г. в 11:35
BCEL is set to produce additional data from a phase 1b trial of its antibody ATRC-101 in multiple solid tumor types. Based on previous data, BCEL has refined the patients it enrolls in the trial, which could improve the strength of the results it produces.
Atreca to Present at Upcoming Investor Conferences
GlobeNewsWire
07 ноя 2022 г. в 16:30
SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming conferences: